Endometriosis treated by Vitamin D (50,000 IU bi-weekly) – RCT Jan 2021

The effect of vitamin D supplementation on clinical symptoms and metabolic profiles in patients with endometriosis

Gynecol Endocrinol. 2021 Jan 29;1-6. doi: 10.1080/09513590.2021.1878138
Abolfazl Mehdizadehkashi 1, Samaneh Rokhgireh 1, Kobra Tahermanesh 1, Neda Eslahi 1, Sara Minaeian 2, Mansooreh Samimi 1

Background: To our knowledge, data on the effects of vitamin D supplementation on clinical symptoms and metabolic profiles in patients with endometriosis are limited. This study was conducted to determine the effects of vitamin D supplementation on clinical symptoms and metabolic profiles in patients with endometriosis.

Methods: The current randomized, double-blind, placebo-controlled trial was conducted among 60 patients (aged 18-40 years old) with endometriosis. Participants were randomly allocated into two groups (30 participants each group) to receive either 50,000 IU vitamin D or placebo each 2 weeks for 12 weeks.

Results: Vitamin D supplementation significantly decreased

• pelvic pain (β - 1.12; 95% CI, -2.1, -0.09; p=.03) and
• total-/HDL-cholesterol ratio (β - 0.29; 95% CI, -0.57, -0.008; p=.04)
  • compared with the placebo.

Moreover, vitamin D intake led to a

• significant reduction in high-sensitivity C-reactive protein (hs-CRP) (β - 0.64 mg/L; 95% CI, -0.97, -0.30; p<.001) and a
• significant increase in total antioxidant capacity (TAC) (β 47.54 mmol/L; 95% CI, 19.98, 75.11; p=.001)
  • compared with the placebo.

Conclusions: Overall, our study demonstrated that vitamin D intake in patients with endometriosis resulted in a significant improvement of pelvic pain, total-/HDL-cholesterol ratio, hs-CRP and TAC levels, but did not affect other clinical symptoms and metabolic profiles.